Abstract 571P
Background
Brain metastases (BM) are common among EGFRm NSCLC patients. And it has been associated with treatment failure and limited survival especially patients with multiple BMs. Dacomitinib is a selective, irreversible, Pan-HER TKI. It brought significant PFS and OS improvement compared with Gefitinib in phase 3 randomize study ARCHER 1050. However, patients with BM or leptomeningeal metastases were excluded in this study. We hereby conducted this phase II study (NCT02047747) to prospectively evaluate the efficacy and safety of Dacomitinib in NSCLC patients with multiple BMs and here are initial results of this study.
Methods
Treatment-naive stage IIIB/IV EGFR-mutant NSCLC patients with multiple and measurable BMs(≥ 3 metastatic lesions in the brain and at least 1 target lesion’s diameter among these lesions should be ≥1 cm) received Dacomitinib45mg orally once daily. Assessments were performed every8 weeks until disease progression (PD) as per RECIST v1.1. End points included PFS, intracranial ORR (iORR), ORR, and safety.
Results
At data cut-off (Jul 1, 2023), a total of 14 patients were enrolled and the median follow-up time was 24 months (range, 4-28m), of which 10 patients had measurable CNS response. For all patients, the mPFS was 15.3m(8/14),ORR was 78.6% while DCR was 100%.The iORR was 80% and iDCR was 100%. The mPFS in patients with 19Del (8/14,57.1%) and21L858R (6/14,42.9%) are 15.3 and 15.2m, ORR are 87.5% and 66.7%, respectively. There are no new adverse events (AEs) compared to ARCHER1050.The most common AEs were rash (10/14; 71.4%), diarrhea (8/14; 57.1%), paronychia (3/14; 21.4%). Temporary discontinuations and dose modification occurred in 2 (14.3%) and 1 (7.1%) patient, respectively.
Conclusions
Dacomitinib showed promising intracranial antitumor activity with a manageable safety profile as first-line therapy in EGFR-mutant NSCLC patients with multiple brain metastases.
Clinical trial identification
NCT02047747.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Funding
Pfizer.
Disclosure
Y. Yu: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Rohce, MSD. Y. Pan: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, Roche, MSD; Financial Interests, Personal, Invited Speaker: Pfizer. J. Zhou: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche, MSD. S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche, Hengrui; Financial Interests, Institutional, Advisory Board: AstraZeneca, Prizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co.Ltd, Roche, Simcere Zaiming Pharmaceutical Co., Ltd.; Financial Interests, Personal, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui, Roche, Hansoh, BeiGene, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Coordinating PI: FibroGen.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract